ClinicalTrials.gg
CompletedNCT03279978Updated Dec 19, 2024Results posted

This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357

A Phase 1 interventional study of BI 730357 and Placebo in Healthy and Psoriasis, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Psoriasis by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Psoriasis · Boehringer Ingelheim.

Enrollment
11th of 18
83 · median 116
Started
2018
with 1 other
Phase 1
4 of 20
none open now
Registered
9th of 20
by date

Among the 20 studies in Psoriasis by Boehringer Ingelheim, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 in phase 1, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 20 studies in Psoriasis by Boehringer Ingelheim is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Psoriasis by Boehringer Ingelheim as a file.
02

Study summary

Phase Ib evaluation of the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) properties of Multiple Rising Dose (MRD) administration of BI 730357 to healthy volunteers for up to 28 days.

03

Conditions studied

  • Healthy
  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the Investigator, based on a complete medical history, physical examination, vital signs (blood pressure, pulse rate), 12-lead (ECG), and clinical laboratory tests
  • Subjects with a partner who is a woman of (WOCBP) must be willing to use male (condom or sexual abstinence) from the first administration of trial medication until 30 days after last administration of trial medication
  • Age of 18 to 45 years (incl.) at screening
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.) at screening
  • Signed and dated written prior to admission to the study in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation

Exclusion criteria

Exclusion criteria

  • Any finding in the medical examination (including blood pressure, pulse rate or (ECG)) deviating from normal and judged as by the Investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the Investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the Investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract (except appendectomy and simple hernia repair) that could interfere with the PK of the trial medication
  • Diseases of the Central Nervous System (CNS) (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or acute infections which are of relevance in the opinion of the Investigator
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc (corrected QT interval) interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
  • Tobacco usage (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Alcohol abuse (consumption of more than 30 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the Investigator; for instance, is considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • Unwillingness to adhere to the rules of UV-light protection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    BI 730357 25 mg fast

    Subjects were orally administered BI 730357 25 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours

    Drug: BI 730357

  • Placebo comparator
    Placebo fast

    Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after a fasting period of at least 6 hours.

    Drug: Placebo

  • Placebo comparator
    Placebo fed

    Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after the intake of a standard continental breakfast.

    Drug: Placebo

  • Experimental
    BI 730357 50 mg fast

    Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours.

    Drug: BI 730357

  • Experimental
    BI 730357 50mg/Placebo

    Subject was orally administered mixed treatment of BI 730357 50 mg and placebo, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours

    Drug: BI 730357 · Drug: Placebo

  • Experimental
    BI 730357 50 mg fed

    Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after the intake of a standard continental breakfast.

    Drug: BI 730357

  • Experimental
    BI 730357 100 mg fast

    Subjects were orally administered BI 730357 100 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours

    Drug: BI 730357

  • Experimental
    BI 730357 200 mg fast

    Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after a fasting period of at least 6 hours

    Drug: BI 730357

  • Experimental
    BI 730357 200 mg fed

    Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.

    Drug: BI 730357 · Drug: Midazolam

  • Experimental
    BI 730357 400 mg fed

    Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 400 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.

    Drug: BI 730357 · Drug: Midazolam

Interventions

  • BI 730357 film-coated tablet

  • DrugPlacebo

    Placebo

  • Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Drug-related Adverse Events (AEs)

    Number of subjects with drug-related Adverse Events (AEs) assessed by the investigator.

    Time frame: From first drug administration until 7 days after last dose, up to 21 days (for 25, 50 and 100 mg dose groups) and up to 35 days (for 200 and 400 mg dose groups)

Secondary outcomes

  1. Area Under the Concentration-time Curve of the Analyte BI 730357 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCtau,1)

    Area under the concentration-time curve of the analyte BI 730357 in plasma over a uniform dosing interval tau after administration of the first dose (AUCtau,1). In this study AUCtau,1 = AUC0-24

    Time frame: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h and 23.5h after first dosing on Day1.

  2. Maximum Measured Concentration of the Analyte BI 730357 in Plasma After Administration of the First Dose (Cmax)

    Maximum measured concentration of the analyte BI 730357 in plasma after administration of the first dose (Cmax)

    Time frame: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h and 23.5h after first dosing on Day1.

  3. Area Under the Concentration-time Curve of BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After Last Dose Administration.

    Area under the concentration-time curve of BI 730357 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.

    Time frame: Day 14 and Day 28 (Please refer description for the time frame in detail)

  4. Maximum Measured Concentration of the Analyte BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ After the Last Dose (Cmax,ss)

    Maximum measured concentration of BI 730357 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups:-0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.

    Time frame: Day 14 and Day 28 (Please refer description for the time frame in detail)

07

Results

Posted Sep 21, 2023

Participant flow

Randomised, placebo-controlled, double-blind design investigating multiple rising doses

Participant flow — Overall Study
MilestonePlacebo FastPlacebo FedBI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50mg/PlaceboBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg Fed
Started11999189999
Completed10889188998
Not completed1110001001
Withdrew: Withdrawal by subject0100000001
Withdrew: Lost to follow-up1010000000
Withdrew: Other than stated above0000001000

Outcome measures

PrimaryNumber of Subjects With Drug-related Adverse Events (AEs)

Number of subjects with drug-related Adverse Events (AEs) assessed by the investigator.

Time frame:
From first drug administration until 7 days after last dose, up to 21 days (for 25, 50 and 100 mg dose groups) and up to 35 days (for 200 and 400 mg dose groups)
Reported as:
Number · Participants
Number of Subjects With Drug-related Adverse Events (AEs)
ParticipantsPlacebo FastPlacebo FedBI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg Fed
Number of Subjects With Drug-related Adverse Events (AEs)421221222
SecondaryArea Under the Concentration-time Curve of the Analyte BI 730357 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCtau,1)

Area under the concentration-time curve of the analyte BI 730357 in plasma over a uniform dosing interval tau after administration of the first dose (AUCtau,1). In this study AUCtau,1 = AUC0-24

Time frame:
-0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h and 23.5h after first dosing on Day1.
Reported as:
Geometric mean · Nanomole (nmol)·hour (h)/ liter(L)
Area Under the Concentration-time Curve of the Analyte BI 730357 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCtau,1)
Nanomole (nmol)·hour (h)/ liter(L)BI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg Fed
Area Under the Concentration-time Curve of the Analyte BI 730357 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCtau,1)2150 ± 31.23590 ± 34.44620 ± 27.96650 ± 26.49240 ± 32.211900 ± 22.615600 ± 24.5
Statistical analysis
  • BI 730357 25 mg Fast vs BI 730357 50 mg Fast vs BI 730357 100 mg Fast vs BI 730357 200 mg Fast · Slope: 0.7124 · 95% CI 0.5702 to 0.8546
  • BI 730357 50 mg Fed vs BI 730357 200 mg Fed vs BI 730357 400 mg Fed · Slope: 0.5964 · 95% CI 0.4777 to 0.7151
SecondaryMaximum Measured Concentration of the Analyte BI 730357 in Plasma After Administration of the First Dose (Cmax)

Maximum measured concentration of the analyte BI 730357 in plasma after administration of the first dose (Cmax)

Time frame:
-0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h and 23.5h after first dosing on Day1.
Reported as:
Geometric mean · Nanomole (nmol)/liter(L)
Maximum Measured Concentration of the Analyte BI 730357 in Plasma After Administration of the First Dose (Cmax)
Nanomole (nmol)/liter(L)BI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg Fed
Maximum Measured Concentration of the Analyte BI 730357 in Plasma After Administration of the First Dose (Cmax)143 ± 25.4247 ± 37.6368 ± 34.8408 ± 32.5537 ± 26.8953 ± 36.51320 ± 24.0
Statistical analysis
  • BI 730357 25 mg Fast vs BI 730357 50 mg Fast vs BI 730357 100 mg Fast vs BI 730357 200 mg Fast · Slope: 0.6445 · 95% CI 0.5124 to 0.7766
  • BI 730357 50 mg Fed vs BI 730357 200 mg Fed vs BI 730357 400 mg Fed · Slope: 0.6223 · 95% CI 0.4747 to 0.7699
SecondaryArea Under the Concentration-time Curve of BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After Last Dose Administration.

Area under the concentration-time curve of BI 730357 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.

Time frame:
Day 14 and Day 28 (Please refer description for the time frame in detail)
Reported as:
Geometric mean · Nanomole (nmol)·hour (h)/ liter(L)
Area Under the Concentration-time Curve of BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After Last Dose Administration.
Nanomole (nmol)·hour (h)/ liter(L)BI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg Fed
Area Under the Concentration-time Curve of BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After Last Dose Administration.4200 ± 50.07550 ± 30.39950 ± 29.414100 ± 24.514600 ± 45.029700 ± 30.031400 ± 38.2
Statistical analysis
  • BI 730357 25 mg Fast vs BI 730357 50 mg Fast vs BI 730357 100 mg Fast vs BI 730357 200 mg Fast · Slope: 0.6401 · 95% CI 0.4545 to 0.8258
  • BI 730357 50 mg Fed vs BI 730357 200 mg Fed vs BI 730357 400 mg Fed · Slope: 0.5811 · 95% CI 0.4013 to 0.7609
SecondaryMaximum Measured Concentration of the Analyte BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ After the Last Dose (Cmax,ss)

Maximum measured concentration of BI 730357 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups:-0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.

Time frame:
Day 14 and Day 28 (Please refer description for the time frame in detail)
Reported as:
Geometric mean · Nanomole (nmol)/ liter(L)
Maximum Measured Concentration of the Analyte BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ After the Last Dose (Cmax,ss)
Nanomole (nmol)/ liter(L)BI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg Fed
Maximum Measured Concentration of the Analyte BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ After the Last Dose (Cmax,ss)277 ± 37.6474 ± 26.7697 ± 26.5793 ± 29.2948 ± 37.51840 ± 27.82260 ± 25.8
Statistical analysis
  • BI 730357 25 mg Fast vs BI 730357 50 mg Fast vs BI 730357 100 mg Fast vs BI 730357 200 mg Fast · Slope: 0.6005 · 95% CI 0.4534 to 0.7477
  • BI 730357 50 mg Fed vs BI 730357 200 mg Fed vs BI 730357 400 mg Fed · Slope: 0.5799 · 95% CI 0.4441 to 0.7156

Adverse events

Collected over From first drug administration until 7 days after last dose, up to 21 days (for 25, 50 and 100 mg dose groups) and up to 35 days (for 200 and 400 mg dose groups). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Fast0/12 (0%)0/12 (0%)8/12 (66.7%)
Placebo Fed0/9 (0%)0/9 (0%)5/9 (55.6%)
BI 730357 25 mg Fast0/9 (0%)0/9 (0%)7/9 (77.8%)
BI 730357 50 mg Fast0/10 (0%)0/10 (0%)6/10 (60%)
BI 730357 50 mg Fed0/8 (0%)0/8 (0%)7/8 (87.5%)
BI 730357 100 mg Fast0/9 (0%)0/9 (0%)4/9 (44.4%)
BI 730357 200 mg Fast0/9 (0%)0/9 (0%)8/9 (88.9%)
BI 730357 200 mg Fed0/9 (0%)0/9 (0%)4/9 (44.4%)
BI 730357 400 mg Fed0/9 (0%)0/9 (0%)6/9 (66.7%)
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPlacebo FastPlacebo FedBI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg Fed
HeadacheNervous system disorders4/123/92/93/101/82/94/92/91/9
DiarrhoeaGastrointestinal disorders0/121/91/91/102/82/92/90/90/9
NasopharyngitisInfections and infestations2/120/92/91/102/80/91/90/91/9
DizzinessNervous system disorders2/121/90/90/100/80/91/90/92/9
Neck painMusculoskeletal and connective tissue disorders0/120/90/90/100/80/92/90/90/9
ErythemaSkin and subcutaneous tissue disorders0/120/90/90/100/80/90/90/92/9
DyspepsiaGastrointestinal disorders0/120/91/90/101/80/90/90/90/9
NauseaGastrointestinal disorders1/120/90/90/101/80/90/90/90/9
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/120/90/90/101/80/90/90/90/9
Seborrhoeic dermatitisSkin and subcutaneous tissue disorders0/120/90/90/101/80/90/90/90/9

Baseline characteristics

Treated set (TS): all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment

Age, Continuous
Age, Continuous(Years)Placebo FastPlacebo FedBI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50mg/PlaceboBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg FedTotal
Mean32.8 ± 7.626.8 ± 5.433.3 ± 7.032.3 ± 7.725.0 ± NA25.4 ± 3.627.3 ± 2.227.1 ± 5.925.6 ± 4.430.6 ± 8.529.1 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo FastPlacebo FedBI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50mg/PlaceboBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg FedTotal
Female00000000000
Male1199918999983
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo FastPlacebo FedBI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50mg/PlaceboBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg FedTotal
Hispanic or Latino00010000001
Not Hispanic or Latino1199818999982
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo FastPlacebo FedBI 730357 25 mg FastBI 730357 50 mg FastBI 730357 50mg/PlaceboBI 730357 50 mg FedBI 730357 100 mg FastBI 730357 200 mg FastBI 730357 200 mg FedBI 730357 400 mg FedTotal
American Indian or Alaska Native00010000001
Asian02000110004
Native Hawaiian or Other Pacific Islander00000000000
Black or African American10000001204
White1079817887974
More than one race00000000000
Unknown or Not Reported00000000000
08

Study locations

1 site
  • CTC North GmbH & Co. KG, Hamburg
    Hamburg, 20251, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2018, 7 months.

Results were first posted in Sep 2023, 5 years after primary completion.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2017
First posted
Sep 12, 2017
StartActual
Jan 9, 2018
Primary completionActual
Aug 24, 2018
CompletionActual
Aug 30, 2018
Results first posted
Sep 21, 2023
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03279978
Responsible party
Sponsor
First posted
Sep 12, 2017
Start date
Jan 9, 2018
Primary completion
Aug 24, 2018
Completion
Aug 30, 2018
Results posted
Sep 21, 2023
Last update
Dec 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevurogant

Start the discussion